While we await data from clinical trials on the efficacy of NAD+ boosters like Nicotinamide Riboside “NR”  (FAQs) (Anecdotes) and Nicotinamide Mononucleotide “NMN” (FAQs and Anecdotes), we’re always on the lookout for comments from experts in the field to hear their current thinking. Earlier this week at an investor conference, Chromadex (NR seller) management had the following to say about NR for Parkinson’s patients (transcript and video below):

Chromadex CEO Rob Fried (At the 27 minute mark):

“There are a couple of indications out there where the data is really quite compelling.

Most of you know about the Parkinson’s data.

To date, there’s a published, peer reviewed Phase 1 study.

There are pre-clinical studies.

We know of another Phase 1 study that we hope will be published shortly.

And they are 3/4 of the way through that Phase 2 clinical study on Parkinson’s disease — of 400 Parkinson’s patients.

So, that is a very interesting opportunity.

We’re waiting to see how that plays out”

Related

FOLLOW us on Twitter @RaisingNAD